Related Experiment Video
Updated: Feb 13, 2026

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
Nivolumab in squamous cell carcinoma of the head and neck
1a Department of Oncology , Antwerp University Hospital , Edegem , Belgium.
Introduction:
The prognosis of recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) after failure of first line chemotherapy is dismal. Until the publication of the results of CheckMate 141, not a single agent provided any survival benefit as a second line treatment for R/M HNSCC. Areas covered: A comprehensive review of the literature was conducted on the role of nivolumab in HNSCC. Expert commentary: Nivolumab is approved by the Food and Drug Administration for the treatment of patients based on the results of CheckMate 141 showing an overall survival benefit as compared to standard care (single agent docetaxel, methotrexate, or cetuximab). Of particular interest are immune-related adverse events which should be managed according to published guidelines.
Insights
Nivolumab offers a survival benefit for recurrent/metastatic head and neck squamous cell carcinoma after chemotherapy failure. This immunotherapy is now FDA-approved, improving outcomes compared to standard treatments.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has a poor prognosis after first-line chemotherapy.
- No single agent previously demonstrated survival benefit in second-line treatment for R/M HNSCC.
Purpose of the Study:
- To review the role of nivolumab in treating R/M HNSCC.
- To evaluate nivolumab's efficacy as a second-line treatment option.
Main Methods:
- Comprehensive literature review on nivolumab in HNSCC.
- Analysis of data from the CheckMate 141 trial.
Main Results:
- Nivolumab demonstrated an overall survival benefit compared to standard chemotherapy (docetaxel, methotrexate, or cetuximab).
- FDA approval granted for nivolumab in this patient population.
Conclusions:
- Nivolumab represents a significant advancement in second-line treatment for R/M HNSCC.
- Management of immune-related adverse events is crucial for patients receiving nivolumab.
More Related Videos
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Muscles of the Anterior Neck
Muscles that Move the Head
The bilateral sternocleidomastoid, or SCM, and the suprahyoid and infrahyoid muscles are significant head flexors. The SCM muscles originate at the sternum and clavicle and attach to the mastoid process of the temporal bone. The SCM contracts bilaterally to bend the head forward, whereas...
Chemistry of the Cell
Water
The polarity of the water molecule and its resulting hydrogen bonding makes water a unique substance with special properties that are intimately tied to the processes of life. Life originally evolved in an aqueous environment, and most of an organism’s cellular chemistry and metabolism occur inside the aqueous contents of the cell’s cytoplasm. Special properties of water are its high heat capacity...
What are Cells?
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...

